Second- and third-generation ALK inhibitors for non-small cell lung cancer

被引：0
作者：
Jingjing Wu
John Savooji
Delong Liu
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[2] Westchester Medical Center and New York Medical College,Department of Medicine
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Brain Metastasis; Pemetrexed; Anaplastic Lymphoma Kinase; Anaplastic Large Cell Lymphoma; Crizotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
引用
收藏
相关论文
共 50 条
  • [1] Second- and third-generation ALK inhibitors for non-small cell lung cancer
    Wu, Jingjing
    Savooji, John
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer
    Bauman, Jessica R.
    Liu, Geoffrey
    Preeshagul, Isabel
    Liu, Stephen V.
    Melosky, Barbara
    Abrahami, Devin
    Li, Benjamin
    Thomaidou, Despina
    Duncan, Kirsten
    Krulewicz, Stan
    Rupp, Martin
    Lin, Jessica J.
    LUNG CANCER, 2024, 195
  • [3] Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
    Spagnuolo, Alessia
    Maione, Paolo
    Gridelli, Cesare
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (03) : 231 - 241
  • [4] Second generation ALK inhibitors in non-small cell lung cancer: Systemic review
    Viala, Marie
    Brosseau, Solenn
    Planchard, David
    Besse, Benjamin
    Soria, Jean-Charles
    BULLETIN DU CANCER, 2015, 102 (04) : 381 - 389
  • [5] Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer
    Shirish M. Gadgeel
    Current Treatment Options in Oncology, 2017, 18
  • [6] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [7] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
  • [8] Brigatinib and the new generation of ALK-inhibitors for non-small cell lung cancer
    McCall, Neal S.
    Lu, Bo
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S380 - S383
  • [9] ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
    Sullivan, Ivana
    Planchard, David
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (01) : 32 - 47
  • [10] The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
    Gristina, Valerio
    La Mantia, Maria
    Iacono, Federica
    Galvano, Antonio
    Russo, Antonio
    Bazan, Viviana
    PHARMACEUTICALS, 2020, 13 (12) : 1 - 23
12345